SCORE2

SCORE2: ESC 2021 10-year fatal and non-fatal CVD risk calculator for European primary prevention.

Demographics

Age (40–69 years)

Sex

Cardiovascular Factors

Systolic BP (mmHg)

Total Cholesterol (mg/dL)

Lifestyle & Comorbidities

Current Smoker

Diabetes Mellitus

Region

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Primary prevention in European and high-income populations

Adults aged 40–69 without prior CVD, diabetes, CKD

Risk-based therapeutic decision-making (blood pressure, lipids)

ESC 2021 guideline–endorsed tool; preferred over SCORE1

Estimates 10-year fatal + non-fatal CVD events (unlike SCORE1)

Key Advantages

Incorporates non-fatal MI and stroke (20–30% of events)

Updated calibration for contemporary European data

Accounts for region-specific CVD mortality variation

Superior to original SCORE1 for modern risk quantification

How it Works

Input Variables

Age (40–69 years)

Sex (male/female)

Systolic blood pressure (treated or untreated)

Total cholesterol or LDL cholesterol

Smoking status (yes/no)

Diabetes (yes/no)

Risk Categories

10-Year Fatal + Non-Fatal CVD Risk	Risk Category	LDL Target (mmol/L)	Action
<1%	Very Low	<3.0	Lifestyle; reassess 5–10 yrs
1–5%	Low	<2.6	Lifestyle predominantly
5–10%	Moderate	<1.8	Consider statin if LDL >1.8; intensify lifestyle
>10%	High+	<1.4	Statin ± ezetimibe/PCSK9i; BP control

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

WHO NewsJul 2, 2026

WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

Clinical Context

We think this has broad domain relevance to SCORE 2.

BJOGJun 25, 2026

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

Clinical Context

We think this has broad domain relevance to SCORE 2.

SCORE2

When to Use

When to Use

Key Advantages

How it Works

Input Variables

Risk Categories

Clinical Pearls

Key Distinctions from SCORE1

CV Risk Modifiers

Next Steps

Very Low (<1%) / Low (1–5%) Risk

Moderate Risk (5–10%)

High (>10%) Risk

Complementary Calculators

The Evidence

Primary Publication

SCORE2 risk prediction algorithms.

Origins & History

Development

Recent Journal Updates

SCORE2

When to Use

When to Use

Key Advantages

How it Works

Input Variables

Risk Categories

Clinical Pearls

Key Distinctions from SCORE1

CV Risk Modifiers

Next Steps

Very Low (<1%) / Low (1–5%) Risk

Moderate Risk (5–10%)

High (>10%) Risk

Complementary Calculators

The Evidence

Primary Publication

SCORE2 risk prediction algorithms.

Origins & History

Development

Recent Journal Updates